Astellas Pharma Inc. - Product Pipeline Review - 2016

  • ID: 3766792
  • Company Profile
  • 285 pages
  • Global Markets Direct
  • Astellas Pharma, Inc.
1 of 4
Astellas Pharma Inc. - Product Pipeline Review - 2016

Summary

The report ‘Astellas Pharma Inc. - Product Pipeline Review - 2016’, provides an overview of the Astellas Pharma Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Astellas Pharma Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Astellas Pharma Inc.
- The report provides overview of Astellas Pharma Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Astellas Pharma Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Astellas Pharma Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Astellas Pharma Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Astellas Pharma Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Astellas Pharma Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Astellas Pharma Inc. Snapshot

Astellas Pharma Inc. Overview

Key Information

Key Facts

Astellas Pharma Inc. - Research and Development Overview

Key Therapeutic Areas

Astellas Pharma Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Astellas Pharma Inc. - Pipeline Products Glance

Astellas Pharma Inc. - Late Stage Pipeline Products

Astellas Pharma Inc. - Clinical Stage Pipeline Products

Astellas Pharma Inc. - Early Stage Pipeline Products

Astellas Pharma Inc. - Drug Profiles

linaclotide

solifenacin succinate

tacrolimus ER

(ipragliflozin + sitagliptin phosphate)

(mirabegron + solifenacin succinate)

amenamevir

ASP-0113

bendamustine hydrochloride

degarelix acetate

enzalutamide

evolocumab

fidaxomicin

gilteritinib fumarate

mirabegron ER

naquotinib mesylate

peficitinib hydrobromide

quetiapine fumarate ER

romosozumab

roxadustat

AGS-16C3F

ASP-1707

ASP-3662

ASP-7962

ASP-8232

erlotinib hydrochloride

FG-2216

ipragliflozin

linsitinib

MA09-hRPE

regadenoson

blinatumomab

AGS-67E

ASG-15ME

ASP-0819

ASP-2205

ASP-2905

ASP-4132

ASP-4345

ASP-5094

ASP-5878

ASP-6282

ASP-6294

ASP-7266

ASP-7398

ASP-8062

enfortumab vedotin

OSI-930

AS-1069562

AS-1669058

AS-1940477

AS-2034178

AS-2077715

AS-2444697

AS-2521780

AS-2575959

AS-2715348

AS-2795440

AS-288640100

ASP-1017

ASP-1645

ASP-3258

ASP-5736

ASP-6537

ASP-7663

ASP-9133

ASP-9726

FK-886

Gene Therapy to Activate mVChR1 for Retinits Pigmentosa

KB-425796C

Monoclonal Antibody Conjugates for Oncology

OSI-296

Small Molecule 2 for Epilepsy

Small Molecule 3 for Epilepsy

Small Molecule 4 for Epilepsy

Small Molecule for Epilepsy

Small Molecule to Block N-type Calcium and hERG Potassium Channels for Neuropathic Pain

Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer

Small Molecule to Inhibit JAK3 for Heart Transplantation

Small Molecule to Inhibit PDE10A for Schizophrenia

Small Molecule to Inhibit TAK1 for Ovarian Cancer

Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine

Small Molecules to Inhibit DAAO for Cognitive Disorders

Small Molecules to Inhibit RANKL for Osteoclastogenesis

Stem Cell Therapy for Autoimmune Diseases

Stem Cell Therapy for Corneal Blindness

Stem Cell Therapy for Glaucoma

Stem Cell Therapy for Ophthalmic Disorders

UMN-0901

AS-1468240

Drugs for Pancreatic Cancer

KB-425796A

Monoclonal Antibodies for Oncology

Small Molecules for Non-Neuromuscular and Neuromuscular Disorders

Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders

Small Molecules to Inhibit ACK1 for Oncology

Astellas Pharma Inc. - Pipeline Analysis

Astellas Pharma Inc. - Pipeline Products by Target

Astellas Pharma Inc. - Pipeline Products by Route of Administration

Astellas Pharma Inc. - Pipeline Products by Molecule Type

Astellas Pharma Inc. - Pipeline Products by Mechanism of Action

Astellas Pharma Inc. - Recent Pipeline Updates

Astellas Pharma Inc. - Dormant Projects

Astellas Pharma Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Astellas Pharma Inc. - Company Statement

Astellas Pharma Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Astellas Pharma Inc. - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Astellas Pharma Inc., Key Information

Astellas Pharma Inc., Key Facts

Astellas Pharma Inc. - Pipeline by Indication, 2016

Astellas Pharma Inc. - Pipeline by Stage of Development, 2016

Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2016

Astellas Pharma Inc. - Combination Treatment Modalities in Pipeline, 2016

Astellas Pharma Inc. - Partnered Products in Pipeline, 2016

Astellas Pharma Inc. - Partnered Products/ Combination Treatment Modalities, 2016

Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2016

Astellas Pharma Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Astellas Pharma Inc. - Pre-Registration, 2016

Astellas Pharma Inc. - Filing rejected/Withdrawn, 2016

Astellas Pharma Inc. - Phase III, 2016

Astellas Pharma Inc. - Phase II, 2016

Astellas Pharma Inc. - Phase I, 2016

Astellas Pharma Inc. - IND/CTA Filed, 2016

Astellas Pharma Inc. - Preclinical, 2016

Astellas Pharma Inc. - Discovery, 2016

Astellas Pharma Inc. - Pipeline by Target, 2016

Astellas Pharma Inc. - Pipeline by Route of Administration, 2016

Astellas Pharma Inc. - Pipeline by Molecule Type, 2016

Astellas Pharma Inc. - Pipeline Products by Mechanism of Action, 2016

Astellas Pharma Inc. - Recent Pipeline Updates, 2016

Astellas Pharma Inc. - Dormant Developmental Projects,2016

Astellas Pharma Inc. - Discontinued Pipeline Products, 2016

Astellas Pharma Inc., Other Locations

Astellas Pharma Inc., Subsidiaries

Astellas Pharma Inc., Key Manufacturing Facilities

List of Figures

Astellas Pharma Inc. - Pipeline by Top 10 Indication, 2016

Astellas Pharma Inc. - Pipeline by Stage of Development, 2016

Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2016

Astellas Pharma Inc. - Partnered Products in Pipeline, 2016

Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2016

Astellas Pharma Inc. - Pipeline by Top 10 Target, 2016

Astellas Pharma Inc. - Pipeline by Route of Administration, 2016

Astellas Pharma Inc. - Pipeline by Molecule Type, 2016

Astellas Pharma Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll